Chart of the day: Check out how bady biomedical segment dragged manufacturing output

It posted an 8.4% contraction in August.

The biomedical segment of the city-state's industrial production (IP) has been lagging for months now, posting a contraction for a third consecutive month.

According to the latest data by Singapore Economic Development Board, the biomedical manufacturing output moved at a slower pace of -8.4% in August.

Lower output of active pharmaceutical ingredients and biological products has been dragging the segment down, registering a contraction of 14.1% in August.

This has offset the pickup in medical technology, which gained a momentum of 12.1% on the back of higher export demand for medical instruments.

Without this weak segment, Singapore's IP growth could have clocked in higher at 2.3%, compared to the 0.1% it recorded for the month.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia